Navigation Links
Researchers study vaccine as potential weapon against aggressive brain tumors
Date:7/24/2012

CHICAGO Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of a type of brain tumor. The trial is studying the vaccine's effect on glioblastoma multiformes (GBM), the most common and aggressive type of primary brain tumor. The trial is an example of a growing trend in cancer research that seeks to understand if vaccines can be used to turn a person's own immune system into a weapon against cancers by slowing the growth of tumors.

GBMs, which occur in up to 10,000 Americans annually, are typically treated with surgical resection of the tumor followed by chemotherapy and radiation treatment. "Glioblastomas are complicated to treat because they are aggressive, fast-growing tumors that are often resistant to standard treatment," said principal investigator James Chandler, MD, co-director of the NBTI and surgical director of neuro-oncology at Northwestern Memorial Hospital. "In this trial, a vaccine is made using the person's own white blood cells, which we hope will have the power to stimulate an immune response to kill brain tumor cells."

The vaccine, called ICT-107, is created by collecting the participant's white blood cells through a process called apheresis, which separates the components in the blood. The white blood cells are then treated to recognize the tumor cells turning them into immune cells, which early research indicates may be able to recognize and attack the tumor cells. Patients receive the vaccine in addition to standard treatment.

"Vaccines hold great promise as potential treatments for all types of cancer," said Chandler, who is also a professor of neurological surgery at Northwestern University Feinberg School of Medicine. "More researchers are looking at this as a way to prompt an immune response to slow tumor growth and fight the cancer."

The phase II trial will examine both safety and efficacy of the ICT-107 vaccine. Researchers seek to enroll approximately 225 participants nationally who are newly diagnosed with a GBM. To be considered for enrollment, a person must be 18 years or older and not have a recurrent disease or any other active malignancy or history of malignancy. They must have undergone surgery to excise the GBM, but have not yet started chemotherapy or radiation. Full inclusion and exclusion criteria can be found on ClinicalTrials.gov.

"GBMs are a devastating diagnosis and these patients unfortunately are not given a great deal of time," said Chandler. "Our goal at Northwestern Brain Tumor Institute is to provide patients with the best options to treat their cancer in a manner that not only gives them longer lives, but also improved quality of life."


'/>"/>

Contact: Megan McCann
memccann@nmh.org
312-926-5900
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. Researchers developing bioadhesive gel to protect women from HIV and HSV infections
2. Researchers find driver of breast cancer stem cell metastasis
3. Researchers unfold the mechanisms underlying blood disorders
4. New lipid screening guidelines for children overly aggressive, UCSF researchers say
5. BUSM researchers identify genetic markers for testosterone, estrogen level regulation
6. UGA researchers develop rapid diagnostic test for pathogens, contaminants
7. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
8. Researchers link Kawasaki Disease in childhood with increased risk of adult heart disease
9. Researchers to use novel metabolomics technology for COPD
10. Researchers hit back at early bodycheck theory
11. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ANGELES (PRWEB) , ... October 12, 2017 , ... ... Parsa Mohebi Hair Restoration, has recently contributed a medical article to the newly ... on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: